GENE SILENCING AGENTS FOR TARGETING CORONAVIRUS GENES AND USES THEREOF
20230138103 · 2023-05-04
Inventors
- Chiang J. LI (Cambridge, MA, US)
- Xiangao Sun (Brookline, MA)
- Charles LI (Cambridge, MA, US)
- Pingping "Peter" KUANG (Lexington, MA, US)
Cpc classification
A61K31/713
HUMAN NECESSITIES
C12N2320/11
CHEMISTRY; METALLURGY
International classification
C12N15/113
CHEMISTRY; METALLURGY
Abstract
The present invention provides gene silencing agents that are capable of silencing the expression of the Coronavirus gene(s), e.g., SARS-CoV-2, both in vitro and in vivo. The present invention further provides general and specific compositions and methods of using such compositions that can be used to reduce specific SARS-CoV-2 protein levels or SARS-CoV-2 titers, in a subject, e.g., a mammal such as a human, for research or therapeutic purposes, for example to manage or treat conditions related to Coronavirus infection, e.g., COVID-19.
Claims
1. (canceled)
2. (canceled)
3. A gene silencing agent for treating COVID-19, wherein the gene silencing agent is a small interfering RNA duplex, comprising an antisense strand having at least 15 or more contiguous nucleotides selected from the group consisting of SEQ ID NOs: 211 to 420, and a sense strand substantially complementary to the antisense strand, the sense strand forming a double-stranded region with the antisense strand.
4. The agent of claim 3, wherein the antisense strand has a length of 15 to 30 nucleotides, the sense strand has a length of 9-29 nucleotides, both ends included.
5. The agent of claim 3, wherein the said antisense strand has a length of 23 nucleotides and the sense strand has a length of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides.
6. The agent of claim 3, wherein the said antisense strand has a length of 21 nucleotides and the sense strand has a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 nucleotides.
7. The agent of claim 3, wherein the said antisense strand has a length of 19 nucleotides and the sense strand has a length of 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 nucleotides.
8. The agent of claim 3, wherein the antisense strand has overhang(s) at the 3′ and/or 5′ ends, wherein the overhang at the 3′ and/or 5′ ends has a length of 1, 2, 3, 4, 5 or 6 nucleotides.
9. The agent of claim 3, wherein the antisense strand has overhang at 3′ end and has a 5′blunt end, wherein the overhang at 3′ end has a length of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 nucleotides.
10. A gene silencing agent for treating COVID-19, wherein said gene silencing agent is a small interfering RNA duplex, comprising an antisense strand comprising a nucleotide sequence that is essentially identical to a sequence selected from the group consisting of SEQ ID NOs: 211 to 420, and a sense strand comprising a nucleotide sequence that is essentially identical to a corresponding sequence selected from the group consisting of SEQ ID NOs: 421 to 630, the sense strand forming a double-stranded region with the antisense strand.
11. The gene silencing agent of claim 10, wherein said antisense strand comprises the sequence of 5′-AACGAUUGCAGCAUUGUUAGC-3′ (SEQ ID NO:253), and said sense strand comprises the sequence of 5′-AACAAUGCUGCAAUC-3′ (SEQ ID NO:463).
12. The gene silencing agent of claim 10, wherein said antisense strand comprises the sequence of 5′-AACUUUAUCAUUGUAGAUGUC-3′ (SEQ ID NO:365), and said sense strand comprises the sequence of 5′-AUCUACAAUGAUAAA-3′ (SEQ ID NO:575).
13. The gene silencing agent of claim 10, wherein said antisense strand comprises the sequence of 5′-AAGCAUUGUUAGCAGGAUUGC-3′ (SEQ ID NO:224), and said sense strand comprises the sequence of 5′-AUCCUGCUAACAAUG-3′ (SEQ ID NO:434).
14. The gene silencing agent of claim 10, wherein said antisense strand comprises the sequence of 5′-AACAAUUUGCGGCCAAUGUUU-3′ (SEQ ID NO:240), and said sense strand comprises the sequence of 5′-CAUUGGCCGCAAAUU-3′ (SEQ ID NO:450).
15. The gene silencing agent of claim 10, wherein said antisense strand comprises the sequence of 5′-AAUUGUUUGGAGAAAUCAUCC-3′ (SEQ ID NO:245), and said sense strand comprises the sequence of 5′-UGAUUUCUCCAAACA-3′ (SEQ ID NO:455).
16. The gene silencing agent of claim 10, wherein said antisense strand comprises the sequence of 5′-AAACCAGCUACUUUAUCAUUG-3′ (SEQ ID NO:366), and said sense strand comprises the sequence of 5′-UGAUAAAGUAGCUGG-3′ (SEQ ID NO:576).
17. The gene silencing agent of claim 10, wherein said antisense strand comprises the sequence of 5′-AAAUGUGUCACAAUUACCUUC-3′ (SEQ ID NO:354), and said sense strand comprises the sequence of 5′-GGUAAUUGUGACACA-3′ (SEQ ID NO:564).
18. The gene silencing agent of claim 10, wherein said antisense strand comprises the sequence of 5′-AACAGCUGGACAAUCCUUAAG-3′ (SEQ ID NO:357), and said sense strand comprises the sequence of 5′-AAGGAUUGUCCAGCU-3′ (SEQ ID NO:567).
19. The agent of claim 3, wherein at least one nucleotide of said antisense strand and/or sense strand is a modified nucleotide.
20. The agent of claim 3, wherein at least one of said antisense strand and sense strand is conjugated to a ligand comprising a lipid moiety such as a cholesterol moiety.
21. The agent of claim 3, wherein the said agent is capable of reducing the levels of SARS-CoV-2 protein, SARS-CoV-2 mRNA or SARS-CoV-2 titer in a cell in a subject.
22-35. (canceled)
Description
BRIEF DESCRIPTION OF FIGURES
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0041] As used herein, the singular form “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells including mixtures thereof.
[0042] When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below those numerical values. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20%, 10%, 5%, or 1%. In some embodiments, the term “about” is used to modify a numerical value above and below the stated value by a variance of 10%. In some embodiments, the term “about” is used to modify a numerical value above and below the stated value by a variance of 5%. In some embodiments, the term “about” is used to modify a numerical value above and below the stated value by a variance of 1%.
[0043] As used herein, the term “nucleoside” means a compound comprising a nucleobase moiety and a sugar moiety. Nucleosides include, but are not limited to, naturally occurring nucleosides (e.g., deoxyribonucleosides and ribonucleosides as found in DNA and RNA) and modified nucleosides. Nucleosides may be linked to a phosphate moiety to become, for example, nucleotides.
[0044] As used herein, the term “nucleotide” means a nucleoside further comprising a phosphate linking group.
[0045] As used herein, the term “gene silencing agent”, comprising RNAi agent or ASO agent, is an unmodified RNA, modified RNA, or nucleoside surrogate, all of which are described herein or are well known in the RNA synthetic art. While numerous modified RNAs and nucleoside surrogates are described, preferred examples include those which have greater resistance to nuclease degradation than do unmodified RNAs. Preferred examples include those that have a 2′ sugar modification, a 5′-modification which includes one or more phosphate groups or one or more analogs of a phosphate group.
[0046] As used herein, the term “RNAi agent” is an RNA agent, which can down-regulate the expression of a target gene, e.g., CoV. While not wishing to be bound by theory, an RNAi agent may act by one or more of a number of mechanisms, including post-transcriptional cleavage of a target mRNA sometimes referred to in the art as RNAi, or pre-transcriptional or pre-translational mechanisms. In some embodiments, an RNAi agent is a double-stranded (ds) RNAi agent. In some embodiments, an RNAi agent is an antisense oligonucleotide.
[0047] As used herein, the term “ds RNAi agent” (abbreviation for “double-stranded RNAi agent”), as used herein, is an RNAi agent which includes more than one, and preferably two, strands in which interchain hybridization can form a region of duplex structure. A “strand” herein refers to a contiguous sequence of nucleotides (including non-naturally occurring or modified nucleotides). The two or more strands may be, or each form a part of, separate molecules, or they may be covalently interconnected, e.g., by a linker, e.g., a polyethyleneglycol linker, to form but one molecule. At least one strand can include a region which is sufficiently complementary to a target RNA. Such strand is termed the “antisense strand”. A second strand comprised in the ds RNAi agent which comprises a region complementary to the antisense strand is termed the “sense strand”. However, a double-stranded (ds) RNAi agent can also be formed from a single RNA molecule which is, at least partly; self-complementary, forming, e.g., a hairpin or panhandle structure, including a duplex region. In such case, the term “strand” refers to one of the regions of the RNA molecule that is complementary to another region of the same RNA molecule. “aiRNA agent” or “aiRNA” and “siRNA agent” or “siRNA” as used herein, refers to an iRNA agent, e.g., a ds RNAi agent, that is sufficiently short that it does not induce a deleterious interferon response in a human cell, e.g., it has a duplexed region of less than 30 nucleotide pairs. “aiRNA agent” or “aiRNA” has two strands that are asymmetric, namely either has overhangs of 1-5 nucleotides at both 3′ and/or 5′ ends of the antisense strand of the agent, or has one blunt end at the 5′ ends of the antisense strand and one overhang of 1-10 nucleotides at the 3′ ends of the antisense strand. “siRNA agent” or “siRNA” has two strands that are substantially symmetric, namely has two overhangs of 1-5 nucleotides at both 3′ ends of the agent. In a preferred embodiment, the ds RNAi agent is aiRNA (asymmetric interfering RNA) molecule(s).
[0048] As used herein, the term “oligonucleotide” refers to a compound comprising a plurality of linked nucleosides. In certain embodiments, one or more of the plurality of nucleosides is modified. In certain embodiment, an oligonucleotide comprises one or more ribonucleosides (as in RNA) and/or deoxyribonucleosides (as in DNA). In some embodiments, the oligonucleotide is a single-stranded oligonucleotide. In some other embodiments, the oligonucleotide is a double-stranded interfering RNA, such as siRNA, aiRNA, shRNA.
[0049] As used herein, the term “modified nucleotide” means a nucleotide having at least one modified sugar moiety, modified internucleoside linkage, and/or modified nucleobase.
[0050] As used herein, the term “modified nucleoside” means a nucleoside having at least one modified sugar moiety, and/or modified nucleobase.
[0051] As used herein, the term “modified oligonucleotide” means an oligonucleotide comprising at least one modified nucleotide.
[0052] As used herein, the term “naturally occurring internucleoside linkage” means a 3′ to 5′ phosphodiester linkage.
[0053] As used herein, the term “modified internucleoside linkage” refers to a substitution or any change from a naturally occurring internucleoside bond. For example, a phosphorothioate linkage is a modified internucleoside linkage.
[0054] As used herein, the term “natural sugar moiety” means a sugar found in DNA (2-H) or RNA (2-OH).
[0055] As used herein, the term “modified sugar” refers to a substitution or change from a natural sugar. For example, a 2′-O-methoxyethyl modified sugar is a modified sugar.
[0056] As used herein, the term “bicyclic sugar” means a furosyl ring modified by the bridging of two non-geminal ring atoms. A bicyclic sugar is a modified sugar.
[0057] As used herein, the term “modified nucleobase” refers to any nucleobase other than adenine, cytosine, guanine, thymidine, or uracil. For example, 5-methylcytosine is a modified nucleobase. An “unmodified nucleobase” means the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U).
[0058] As used herein, “modulating”, “regulating” and its grammatical equivalents refer to either increasing or decreasing (e.g., silencing), in other words, either up-regulating or down-regulating. As used herein, “gene silencing” refers to reduction of gene expression and may refer to a reduction of gene expression about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% of the targeted gene.
[0059] As used herein, the term “subject” refers to any animal (e.g., a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment. Typically, the terms “subject” and “patient” are used interchangeably herein in reference to a human subject.
[0060] Terms such as “treating” or “treatment” or “to treat” or “alleviating” or “to alleviate” as used herein refer to both (1) therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder and (2) prophylactic or preventative measures that prevent or slow the development of a targeted pathologic condition or disorder. Thus, those in need of treatment include those already with the disorder; those prone to have the disorder; and those in whom the disorder is to be prevented. A subject is successfully “treated” according to the methods of the present invention if the patient shows one or more of the following: a reduction in the number of or complete absence of cancer cells; a reduction in the tumor size; inhibition of or an absence of cancer cell infiltration into peripheral organs including the spread of cancer into soft tissue and bone; inhibition of or an absence of tumor metastasis; inhibition or an absence of tumor growth; relief of one or more symptoms associated with the specific cancer; reduced morbidity and mortality; and improvement in quality of life.
[0061] As used herein, the terms “inhibiting”, “to inhibit” and their grammatical equivalents, when used in the context of a bioactivity, refer to a down-regulation of the bioactivity, which may reduce or eliminate the targeted function, such as the production of a viral protein or a viral mRNA. In particular embodiments, inhibition may refer to a reduction of about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% of the targeted expression.
[0062] As used herein, the term “substantially complementary” or “complementary” refers to complementarity in a base-paired, double-stranded region between two nucleic acids and not any single-stranded region such as a terminal overhang or a gap region between two double-stranded regions. The complementarity does not need to be perfect; there may be any number of base pair mismatches, for example, between the two nucleic acids. However, if the number of mismatches is so great that no hybridization can occur under even the least stringent hybridization conditions, the sequence is not a substantially complementary sequence. When two sequences are referred to as “substantially complementary” herein, it means that the sequences are sufficiently complementary to each other to hybridize under the selected reaction conditions. The relationship of nucleic acid complementarity and stringency of hybridization sufficient to achieve specificity is well known in the art. Two substantially complementary strands can be, for example, perfectly complementary or can contain from 1 to many mismatches so long as the hybridization conditions are sufficient to allow, for example discrimination between a pairing sequence and a non-pairing sequence. Accordingly, substantially complementary sequences can refer to sequences with base-pair complementarity of at least, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or any number in between, in a double-stranded region.
[0063] As used herein, “fully complementary” or “100% complementary” means each nucleobase of a nucleobase sequence of a first nucleic acid has a complementary nucleobase in a second nucleobase sequence of a second nucleic acid. In certain embodiments, a first nucleic acid is an antisense strand and a second nucleic acid is a target nucleic acid. In certain embodiments, a first nucleic acid is a sense strand and a second nucleic acid is an antisense strand.
[0064] As used herein, “essentially identical” when used referring to a first nucleotide sequence in comparison to a second nucleotide sequence means that the first nucleotide sequence is identical to the second nucleotide sequence except for up to one, two or three nucleotide substitutions (e.g., adenosine replaced by uracil).
[0065] As used herein, “hybridization” means the annealing of complementary nucleic acid molecules. In certain embodiments, complementary nucleic acid molecules include a sense strand and an antisense strand. In certain embodiments, complementary nucleic acid molecules include an antisense strand and a target nucleic acid.
[0066] As used herein, “N gene” means the Nucleocapsid region of CoV genome as target gene, preferred example is the Nucleocapsid region of SARS CoV-2 genome, namely, region 28374-29530 of GenBank accession #MN908947.3. Nucleocapsid plays an important role in CoV assembly.
[0067] As used herein, “RdRp gene”, “POL gene” or “P gene” means the RdRp (RNA dependent RNA polymerase) region of CoV genome as target gene, preferred example is the RdRp region of SARS CoV-2 genome, which is known as the Non-structural protein 12 (Nsp12) of SARS CoV-2 genome, namely region 13468-16237 of GenBank accession #MN908947.3. RdRp plays an important role in CoV replications.
[0068] As used herein, “3CL gene” means the 3C-like protease region of CoV genome as target gene, preferred example is the 3CL region of SARS CoV-2 genome, namely, region 10052-10988 of GenBank accession #MN908947.3.
[0069] As used herein, “PL1 gene” means the Papain-like 1 protease region of CoV genome as target gene, preferred example is the PL1 region of SARS CoV-2 genome, namely, region 5123-5929 of GenBank accession #MN908947.3.
[0070] The terms “administer,” “administering,” or “administration” are used herein in their broadest sense. These terms refer to any method of introducing to a subject a compound or pharmaceutical composition described herein and can include, for example, introducing the compound systemically, locally, or in situ to the subject. Thus, a compound of the present disclosure produced in a subject from a composition (whether or not it includes the compound) is encompassed in these terms. When these terms are used in connection with the term “systemic” or “systemically,” they generally refer to in vivo systemic absorption or accumulation of the compound or composition in the blood stream followed by distribution throughout the entire body.
[0071] The terms “effective amount” and “therapeutically effective amount” refer to that amount of a compound or pharmaceutical composition described herein that is sufficient to affect the intended result including, but not limited to, disease treatment, as illustrated below. In some embodiments, the “therapeutically effective amount” is the amount that is effective for detectable killing or inhibition of the growth or spread of cancer cells, the size or number of tumors, and/or other measure of the level, stage, progression and/or severity of the cancer. In some embodiments, the “therapeutically effective amount” refers to the amount that is administered systemically, locally, or in situ (e.g., the amount of compound that is produced in situ in a subject). The therapeutically effective amount can vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of cell migration. The specific dose may vary depending on, for example, the particular pharmaceutical composition, subject and their age and existing health conditions or risk for health conditions, the dosing regimen to be followed, the severity of the disease, whether it is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
[0072] The term “pharmaceutical composition” is a formulation containing the disclosed Gene Silencing Agent in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler, or a vial. The quantity of active ingredient in a unit dose of composition is an effect the amount and is varied according to the particular treatment involved. One skilled in the art will appreciate that it is sometimes necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intranasal, and the like. Dosage forms for the topical or transdermal administration of a silencing agent of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
SARS-CoV-2 and its Genome
[0073] SARS-CoV-2 is a SARS-like corona virus. The closest virus to SARS-CoV-2 identified so far is a virus that originated from the Rhinolophus bat, showing >96% sequence homology (Fisher and Heymann, 2020). SARS-CoV-2 is only 79% homologous with the original SARS-CoV (Zhou et al, 2020).
[0074] The genome of SARS coronaviruses consists of a single-stranded, positive-sense RNA molecule approximately 30 kb in length (Marra et al., 2003). The large SARS-CoV RNA genome produces eight 3′-co-terminal, nested subgenomic mRNAs (sg-mRNAs) for the efficient translation of structural and accessory proteins (Masters, 2006). The 5′ two-thirds of the SARS-CoV genome encode two large replicase polyproteins, expressed by open reading frames (ORF) 1a and 1b. As in other coronaviruses, ORF1a and ORF1b are slightly overlapped and, because ORF1b lacks its own translation initiation sites, proteins encoded by ORF1b are only translated as a fusion protein together with ORF1a by programmed −1 ribosomal frameshifting (−1 PRF; Baranov et al., 2005). The ORF1a and ORF1a/1b fusion proteins are proteolytically cleaved into 16 mature nonstructural proteins (nsps) that play multiple crucial roles during viral genome replication (Masters, 2006). The −1 PRF is thought to be essential for CoV genome replication because the coronavirus RNA-dependent RNA polymerase (RdRp), the key component of the replicase required for viral genome replication (Xu et al., 2003), is the first part of the ORF1a/1b protein synthesized after frameshifting.
[0075] CoVs enter the host cell using the endosomal pathway and/or the cell surface non-endosomal pathway. CoVs disassemble inside the host cell and release the nucleocapsid and viral RNA into the cytoplasm, after which ORF1a/b is translated into polyprotein 1a (pp1a) and 1ab (pp1ab), and the genomic RNA is replicated. (Chan et al, 2015). Subgenomic mRNAs are then synthesized and translated to produce the structural and accessory proteins (van Boheemen, 2012). The helical nucleocapsid, formed by the assembly of nucleocapsid protein (N) and genomic RNA, then interacts with surface protein (S), envelope protein (E), and membrane protein (M) to form the assembled virion (Chan et al, 2015). The virion is eventually released into the extracellular compartment by exocytosis and the viral replication cycle is repeated (Chan et al, 2015).
Design and Selection of Gene Silencing Agent
[0076] The present invention is based on the demonstration of target gene silencing of a SARS-CoV-2 gene in vitro. Based on these results, the invention specifically provides a gene silencing agent that can be used in treating viral infection, particularly CoVs and in particular SARS-CoV-2 infection, in isolated form and as a pharmaceutical composition.
[0077] The gene silencing agents of the present invention have been designed to target regions in the CoV genome, particular SARS-CoV-2 genome, that are most conserved domains to avoid, as much as possible, potential mutations happening in the target site. In addition, the gene silencing agents of the present invention have been designed to inhibit the crucial step of the CoV life cycle, e.g., assembly and replication. Recent Covid19 viral investigations indicate that Nucleocapsid (N) and RdRp (P) regions have a lower mutation rate than others such as the S protein. In some embodiments, the gene silencing agents of the present invention have been designed to target Nucleocapsid (N) and RdRp regions in SARS-CoV-2.
[0078] Such agents can be a single-stranded oligonucleotide or a double-stranded (ds) RNAi agent comprising an antisense strand having at least 15 or more contiguous nucleotides that are substantially complementary to a SARS-CoV-2 gene sequence, particularly, the PL1, 3CL, RdRp and N gene sequences of SARS-CoV-2, and more specifically, target sequences provided in
[0079] The present invention provides gene silencing agent comprising an antisense strand comprising a sequence of at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides which is substantially complementary to, as defined above, at least a portion of a gene from a CoV, particularly the PL1, 3CL, RdRp and N gene of SARS-CoV-2. Exemplified antisense strand of the gene silencing agent, including ASO, siRNA and aiRNA, comprise 15 or more contiguous nucleotides differing by no more than 3 nucleotides from one of the designed antisense strands provided in
[0080] The gene silencing agent is a ds RNAi agent comprising an antisense strand having at least 15 or more contiguous nucleotides that are substantially complementary to a SARS-CoV-2 gene sequence, and a sense strand having at least 12 or more contiguous nucleotides that are substantially complementary to the antisense strand sequence. Particularly useful agents are ds RNAi agents comprising an antisense strand that consist of, consist essentially of or comprise a nucleotide sequence substantially complementary to a sequence from the PL1, 3CL, RdRp and N gene of SARS-CoV-2, more specifically, target sequences provided in
[0081] The antisense strands of the ds RNAi agents of the present invention are based on and comprise at least 15 or more contiguous nucleotides from one of the ds RNAi agents shown to be active in
[0082] Accordingly, the present invention provides ds RNAi agents comprising a sense strand and an antisense strand each comprising a sequence of at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 nucleotides targeting a gene from a CoV, particularly the PL1, 3CL, RdRp and N genes of SARS-CoV-2. Exemplified ds RNAi agents include those that comprise 15 or more contiguous nucleotides from one of the agents provided in
[0083] In certain embodiments, the antisense strand of the gene silencing agent is 10 to 30 nucleotides in length. In other words, antisense strands are from 10 to 30 linked nucleobases. In other embodiments, the antisense strand comprises a modified oligonucleotide consisting of 8 to 100, 10 to 80, 10 to 50, 10 to 30, 12 to 50, 12 to 30, 14 to 30, 14 to 27, 15 to 23, 16 to 23, 19 to 23, or 21 linked nucleobases. In certain such embodiments, the antisense strand comprises a modified oligonucleotide consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 linked nucleobases in length, or a range defined by any two of the above values.
[0084] In certain embodiments, the sense strand of the gene silencing agent is 9 to 30 nucleotides in length. In other words, sense strands are from 9 to 30 linked nucleobases. In other embodiments, the sense strand comprises a modified oligonucleotide consisting of 8 to 100, 10 to 80, 10 to 50, 10 to 30, 12 to 50, 12 to 30, 12 to 20, 12 to 17, 14 to 30, 14 to 20, 14 to 17, 15 to 23, 15 to 16, or 15 linked nucleobases. In certain such embodiments, the sense strand comprises a modified oligonucleotide consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 linked nucleobases in length, or a range defined by any two of the above values.
[0085] In certain embodiments, the ds RNAi agent is an aiRNA molecule. Typically, the aiRNA agent comprises a short RNA duplex having a shorter sense strand and a longer antisense strand, wherein the duplex contains overhangs at the 3′ and/or 5′ ends of the antisense strand. In certain embodiments, the antisense strand has a 3′-overhang from 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides and a 5′-overhang from 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides. In another embodiment, the antisense strand has a 3′-overhang from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides and a 5′ blunt end. In yet another embodiment, the antisense strand has a 5′-overhang from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides and a 3′ blunt end.
[0086] In certain configurations, the aiRNA comprises modified nucleotides. The modified aiRNA is more resistant to degradation and less likely to elicit an immune response compared to a corresponding unmodified aiRNA sequence; while retaining RNAi activity against the target gene. Further, such modifications allow gene silencing at therapeutically viable aiRNA doses with very low cytokine induction, toxicity, and off-target effects associated with the use of unmodified aiRNA. In some configurations, the modified aiRNA contains at least one 2′-O-methyl (2′OMe) purine or pyrimidine nucleotide such as a 2′OMe-uridine, 2′OMe-adenosine, 2′OMe-guanosine, and/or 2′OMe-cytosine nucleotide. In some configurations, the modified aiRNA contains at least one 2′-deoxy-2′-fluoro nucleotide. The modified nucleotides can be present in one strand (i.e., sense or antisense) or both strands of the aiRNA.
[0087] In certain configuration, aiRNA duplexes of various lengths (e.g., 9-23, 14-21, 15-19, 15-21, 14-19, or 14-20 base pairs, more typically 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 base pairs) may be designed with overhangs at the 3′ and/or 5′ ends of the antisense strand. In certain instances, the sense strand of the aiRNA molecule is about 9-23, 14-21, 15-19, 15-21, 14-19, or 14-20 nucleotides in length, more typically 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides in length. In certain other instances, the antisense strand of the aiRNA molecule is about 15-50, 15-40, or 15-30 nucleotides in length, more typically about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25, or 19, 20, 21, 22 or 23 nucleotides in length, and preferably about 19-23 nucleotides in length.
[0088] In certain configuration, the present invention provides designed aiRNA duplexes contain 15mer sense strand (ss) and 21mer antisense strand (as), targeting four regions of the SARS-CoV-2 genome including the Nucleocapsid region (28374-29530), RdRp (P) region (13468-16237), 3CL region (10052-10988) and PL1 region (5123-5929), particularly, targeting the Nucleocapsid (N) region and RdRp region.
[0089] In some configurations, the 5′ antisense overhang contains one, two, three, or more nontargeting nucleotides (e.g., AA, UU, dTdT, etc.). In other configurations, the 3′ antisense overhang contains one, two, three, or more nontargeting nucleotides (e.g., AA, dTdT, etc.). In certain configurations, the 5′ terminal nucleotide and the first nucleotide adjacent to the 5′ terminal nucleotide of the antisense strand is an “AA” motif, a “UU” motif, a “CC” motif, an “AU” motif, an “AC” motif, a “UA” motif, a “UC” motif, or a “CA” motif, or a “dTdT” motif. In a prefer configuration, the 5′ terminal nucleotide and the first nucleotide adjacent to the 5′ terminal nucleotide of the antisense strand comprise an “AA” motif. In some configurations, the last nucleotide of antisense strand at 3′ end consists of an A, U, G or C ribonucleotide.
[0090] In some configurations, the gene silencing agent molecules may comprise one or more modified nucleotides, e.g., in the double-stranded region and/or in the single-stranded region. Typically, these modifications include deoxyribonucleosides, 2′OMe nucleotides (such as, for example, 2′OMe-uridine nucleotides, 2′OMe-adenosine nucleotides, 2′OMe-cytosine nucleotides, or 2′OMe-guanosine nucleotides.), 2′-fluorine nucleotides (2′-deoxy-2′-fluoro nucleotides), 2;-MOE nucleotides, LNA, cEt Morpholine and/or a phosphorothioate (P═S), phosphodiester (P═O) or Thio-phosphoramidate internucleoside linkage, and/or a 5′-Me C nucleotides.
[0091] In some configurations, the gene silencing agents can be further modified so as to be attached to one or more ligands, moieties or conjugates that is selected to improve stability, distribution or cellular uptake of the agent. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., beryl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyloxycholesterol moiety. In one embodiment, a ligand alters the distribution, targeting or lifetime of a gene silencing agent into which it is incorporated. In preferred embodiments, a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. Preferred ligands will not take part in duplex pairing in a duplexed nucleic acid. Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide. In some configurations, the ligands, moieties or conjugates can be conjugated to the 3′ terminus of the sense strand through any linker known to one skilled in the art. In some configurations, the ligands, moieties or conjugates can be conjugated to the 5′ terminus of the sense strand through any linker known to one skilled in the art. In some configurations, the ligands, moieties or conjugates can be conjugated to the 3′ terminus of the antisense strand through any such linker. In some configurations, the ligands, moieties or conjugates can be conjugated to the 5′ terminus of the antisense strand through any such linker.
[0092] In some configurations, the anti sense strand and/or the sense strand contains an overall GC content of 20-70%. In a further embodiment, the GC content is less than 50%, or preferably 30-50%.
[0093] Suitable aiRNA/siRNA/ASO sequences can be designed, selected, synthesized, and modified using any means known in the art.
a) Design and Selection of aiRNA Sequences
[0094] Lead aiRNA sequences were generated and ranked through a custom bioinformatics-based approach. A list of all possible aiRNA target sequences was generated by splitting the SARS-CoV-2 mRNA transcript sequences found in NCBI into all possible 19 base pair target sequences. Regions of sequence divergence were then removed, to avoid targeting polymorphic sequences. Excessively high GC content in a sequence can lead to difficulty unwinding due to high thermodynamic stability whereas excessively low GC content can lead to reduced binding to target sequences. As such, sequences with excessively high or low GC Content, as defined by >70% or <25% respectively, were removed. (GC Content is calculated as the percentage of guanine and cytosine bases in the target sequence). Sequences with four or more consecutive identical bases (e.g., AAAA, TTTT, CCCC, GGGG) were also removed as these were unlikely to properly anneal. The remaining sequences were screened for their ability to silence the expression of the gene of interest (GOI), beginning with sequences with the highest likelihood of efficacy as determined by the presence of patterns associated with previously found high efficacy sequences.
[0095] In certain embodiments, the gene silencing agent comprises an antisense strand consisting of, consisting essentially of or comprising a sequence same with at least 15 contiguous nucleotides differing by no more than 3 nucleotides from one of the sequences of SEQ ID NOS: 211 to 420. In certain embodiments, the antisense strand consists of, consists essentially of or comprises a sequence same with at least 19 contiguous nucleotides differing by no more than 3 nucleotides from one of the sequences of SEQ ID NO.: 211 to 420. In certain embodiments, the antisense strand consists of, consists essentially of or comprises a sequence selected from SEQ ID NO.: 211 to 420.
b) Generating aiRNA Molecules
[0096] aiRNA are typically generated via solid-phase chemical synthesis using the phosphoramidite method (Beaucage et al., 1981). However, the individual oligonucleotides that make up the aiRNA molecules can be synthesized by any variety of techniques described in the literature for oligonucleotide synthesis, including liquid-phase or solid-phase phosphodiester, phosphotriester, phosphite triester, or H-phosphonate chemistry (Reese et al., 2005). Standard oligonucleotide synthesis makes use of common nucleic acid protecting groups, such as dimethoxytrityl at the 5′ end and benzoyl, isobutyryl or acetyl on heterocyclic bases. Furthermore, aiRNA synthesis for applications in vivo often incorporates chemical modifications that improve serum stability and reduce off-target effects, such as 2′-O-methyl and 2′-fluoro modifications to the sugar backbone (Behlke 2009). Computer-controlled, automated oligonucleotide synthesizers such as the Mermade series from Bioautomation (Irving, Tex.) can be used for high-throughput production of aiRNA molecules (Rayner et al. 1998). aiRNA can be synthesized on these and similar instruments at a 0.2 μmol or 1.0 μmol scale, although larger and smaller scale syntheses are also possible. Suitable reagents for RNA synthesis, deprotection and purification are commercially available from a variety of manufacturers. Standard protocols for these processes are readily available in the literature and/or direct from the manufacturer.
Evaluation of Candidate RNAi Agents
[0097] Screening of SARS-CoV-2 aiRNAs
[0098] Not all sequences within a specific messenger RNA are suitable targets for RNA interference. For instance, it is well known that secondary structures in the messenger RNA molecule can prevent the hybridization of the anti-sense strand, an essential step for RNA interference. A proprietary algorithm was employed to guide the selection of aiRNAs, see section “Design and selection of aiRNA sequences”. Subsequently, the efficacy of aiRNAs was verified in vitro assays.
[0099] To test the efficacy of aiRNAs in vitro, aiRNAs can be delivered to cells expressing the GOI. Methods well known in the art, such as encapsulation of aiRNAs in liposomes that are then taken up by the cells, can be used to deliver the aiRNAs. Subsequently, one can assess the efficacy with which a specific aiRNA suppresses the GOI by comparing the expression level of the GOI in cells that received empty liposomes, or an unspecific aiRNA (e.g., aiRNA that does not target the GOD, with the expression of the GOI in cells that received the specific aiRNA. The expression of the GOI can be studied on the RNA as well as the protein level, using techniques well known in the art, such as quantitative PCR for RNA, and Immunoblot or ELISA for protein.
Synthesis of Duplex aiRNAs
[0100] A proprietary algorithm to guide the selection of aiRNAs from the predicted mRNA sequence of SARS-CoV-2 is employed. Selected candidate aiRNAs are showed (See
[0101] To identify aiRNAs that efficiently suppress expression of SARS CoV-2 genes, we subcloned the relevant viral sequences (based on the known SARS CoV-2 genome;
Example 1: In Vitro Screening of all Candidate aiRNAs that Silence SARS-CoV-2 Gene Expression in Mammalian Cells
[0102] The Dual-Luciferase COVID-19 reporter (DLR) plasmids psiCHECK2/PL1, psiCHECK2/3CL, psiCHECK2/RdRp (P) and psiCHECK2/Nucleocapsid (N), containing a synthetic version of the Renilla luciferse (hRluc) gene and a synthetic firefly luciferase (hluc), were constructed to test the activity of COVID-19 aiRNAs. SARS-CoV-2 sequence regions PL1 (5123-5929) 3CL (10052-10988), RdRp (13468-16237), and N (28374-29530) (See
[0103] HeLa cells were grown in DMEM medium, supplemented with fetal calf serum, penicillin, and streptomycin. Sense and antisense aiRNA strands were chemically synthesized on a Mermade 192 oligonucleotide synthesizer. HeLa cells were plated at 10000 cells/well into 96-well culture plates. 24 hours later, these cells were co-transfected with reporter plasmid DNA and various concentrations of COVID-19 aiRNAs (10 pM, 100 pM, 1 nM), unspecific siRNA (negative control) or mock-transfected, using Lipofectamine 2000 reagent. 24 hours post-transfection, the effect of each aiRNA on COVID-19 gene expression was determined by Dual-Glo Luciferase Assay System. Screening results are shown in
Example 2: In Vitro Screening of N Targeting aiRNAs (GHI_N1 to GHI_N96) and RdRp Targeting aiRNAs (GHI_P97 to GHI_P162) in Mammalian Cells
[0104] Construction of Dual-Luciferase Reporter (DLR) system
[0105] Two DLR reporter plasmids including psiCheck-2/Nucleocapsid (N) and psiCheck-2/RdRp (P) were constructed. In brief, from Genbank accession number MN908947.3 (SARS-COV-2 isolate Wuhan-Hu-1), the target regions RdRp (13468-16237) and N (28374-29530) were chemically synthesized by Integrated DNA Technologies (IDT) and were amplified by PCR. Restrictions sites for XhoI and NotI were added to forward and reverse primers, respectively. The PCR amplified P and N fragments were cloned into the psiCheck-2 vector (Promega), in which two luciferase genes (Firefly and Renilla) driven by separate promoters are present. Targeting fragment inserts were cloned into a region immediately following the Renilla luciferase gene, which serves as the reporter, while the Firefly luciferase gene is internal control.
[0106] Cell culture and Transfection
[0107] Anti-SARS-CoV-2 activities of aiRNAs were studied in human cervical cancer cell line HeLa. The cells were cultured in Dulbecco's modified Eagle's medium-1X (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin at 37° C. in a humidified atmosphere of 5% CO.sub.2.
[0108] For 96 wells, HeLa cells were seeded in 100 uL DMEM media without antibiotics to reach 70%-80% confluence at the time of transfection. The reporter plasmid psiCheck-2/N or psiCheck-2/P and aiRNA-cholesterol conjugates were co-transfected using Lipofectamine 2000 (Invitrogen) in the OptiMEM-I reduced-serum media (Invitrogen). Twenty-four hours after transfection, the luminescence activity of the Firefly-luciferase and Renilla-luciferase in each well was detected by using the standard Dual-Luciferase Reporter kit protocol (Promega standard DLR® assay system). The luminescence ratios of Renilla-luciferase/Firefly-luciferase were calculated against the control of untreated aiRNAs.
[0109] Preparation of Transfection Mixture
[0110] The transfection mixtures A & B were prepared separately: 25 uL of two-component mixture-A contained 0.2 uL Lipofectamine-2000 reagent and the remaining volume of OptiMEM media; 25 uL of three-component mixture-B contained 200 ng of reporter plasmid DNA (N or P), 2.5 uL single dose testing concentration of corresponding aiRNA-cholesterol conjugate in PBS buffer plus the remaining volume of OptiMEM media. Mix both A and B solutions in a 1:1 ratio, before adding 50 uL resultant transfection mixture into each well incubated for 5 min at room temperature.
[0111] Screening Results
[0112] The results of all designed candidate N targeting aiRNAs (GHI_N1 to GHI_N96) at concentration of 1 nM are showed in
TABLE-US-00001 TABLE 1 IC.sub.50 concentrations of the most effective N targeting aiRNAs Duplex ID IC.sub.50 (pM) GHI_N14 2.48 GHI_N30 12.21 GHI_N35 22.54 GHI_N43 5.8
[0113] The results of designed candidate RdRp targeting aiRNAs (GHI_P97 to GHI_P144) at concentration of 1 nM are showed in
TABLE-US-00002 TABLE 2 IC.sub.50 concentrations of the most effective RdRp targeting aiRNAs Duplex ID IC.sub.50 (pM) GHI_P144 45.48 GHI_P147 51.34 GHI_P155 17.08 GHI_P156 35.2
Example 3: In Vitro SARS-Cov-2 Viral Infection on Assay of N Targeting aiRNAs (GHI_N35, GHI_N43 and GHI_N81) and RdRp Targeting aiRNAs (GHI_P144, GHI_P147, GHI_P155 and GHI_P156) in Vero E6 Cells
[0114] Materials
[0115] Vero E6 cells were maintained in Eagle's Minimum Essential Medium (EMEM; Gibco Invitrogen) supplemented with 10% fetal bovine serum (FBS; Gibco Invitrogen) in a humidified atmosphere containing 5% CO.sub.2 at 37° C.
[0116] The clinical isolate 2019-nCoV (SARS-CoV-2) was propagated in Vero E6 cells, and the virus titer was determined by measuring 50% tissue culture infectious dose (TCID.sub.50) using immunofluorescence assay. All infection experiments were carried out in a Biosafety Level 3 (BLS-3) laboratory.
[0117] Each aiRNA compound or a combination of 1:1 ratio of aiRNA N43 and aiRNA P155 to be tested was dissolved in saline at a concentration of 1 mM as the stock solution. Five serial dilutions with concentrations at 100 μM, 33 μM, 10 μM, 3.3 μM, 1 μM, were prepared from the stock solution.
[0118] Evaluation Methods
[0119] Vero E6 (10,000 cells/well) cells cultured in EMEM (10% FBS) were inoculated into a 96-well plate and incubate in a humidified atmosphere containing 5% CO.sub.2 at 37° C. for 24 hours. Samples of 10 μL of the above 1-100 μM dilutions were taken at each concentration point, and added into the 100 μL well plate to pretreat the cells for at least 48 hours; 1X Buffer was set as a negative control. The concentrations of test compounds after addition were as follows: 10 μM, 3.3 μM, 1 μM, 333 nM, 100 nM and 0.
[0120] Aliquots of SARS-CoV-2 virus (MOI of 0.05) were added to infect the treated cell populations for 2 hours. The virus-aiRNA compounds mixture was then removed, and the cells were further cultured with fresh medium containing the aiRNA compounds (concentration same with the pretreatment). After 48 hours of incubation, the cell supernatant was collected and lysed in lysis buffer (Takara, 9766) for quantitative analysis.
[0121] After samples of 100 μL of cell culture supernatant were collected from each cell population, viral RNA was isolated using MiniBEST Universal RNA Extraction Kit (TaKaRa, 9766). Viral RNA was eluted in 30 μL ribonuclease-free water. Reverse transcription was performed with a PrimeScript RT Reagent Kit with gDNA Eraser (Takara RR047A); qRT-PCR was performed on StepOnePlusTM Real-time PCR system (Applied Biosystem) with TB Green Premix Ex Taq II (Takara RR820A). The dose-response curves were plotted from viral RNA copies versus the drug concentrations using GraphPad Prism®. Results are shown in
Example 4: Inhibition of SARS-COV-2 Viral Infection and Replication In Vitro by aiRNAs
[0122] Designed test combination (GH543) was a combination of 1:1 ratio of aiRNA N43 compound and aiRNA P155 compound. The test evaluated the ability of the compound to inhibit virus production in Ver E6 cell culture. This assay was a two-step process, where the virus was first produced in cultures containing the antiviral substance at varying dilutions, followed later by titration of the samples for virus titer by endpoint dilution in 96-well microplates. Eight dilutions of the test compound were assayed, and the effective antiviral concentration determined by regression analysis. The toxicity of the test compound was determined in parallel.
[0123] Materials and Methods
[0124] SARS-CoV-2, USA-WA1/2020 stocks were prepared by passaging the virus in African green monkey kidney epithelial cell line (Vero 76) using test media of modified eagle's medium (MEM) supplemented with 2% heat-inactivated fetal bovine serum (FBS) and 50 g/mL gentamicin. Both aiRNA-1 (100 μM) and aiRNA-2 (100 μM) were mixed at a 1:1 ratio to prepare the 50 μM GH543. A 29.1 μM solution was then prepared in 1×RNAi buffer. Eight serial half-log dilutions were performed in 1x RNAi buffer, then 10 μL of each prepared concentration was added to 40 μL reduced serum MEM (OptiMEM). This solution was mixed with the prepared GH543 solutions at a 1:1 ratio (50 μL+50 μL). The compound was incubated for 20 minutes at room temperature. Each prepared dilution was then added in 13.75 μL for 5 wells of a 96-well plate containing 186.25 μL test media with 80-100% confluent Vero E6 cells. The final highest concentration on the plate was 200 nM.
[0125] The test combination (GH543) was prepared as above. Compound dilutions were incubated with cells for 24 hours prior to infection with SARS-CoV-2. SARS-CoV-2 was prepared to achieve the lowest possible multiplicity of infection (MOI of 0.001) that would yield >80% cytopathic effect (CPE) within 5 days. The protease inhibitor (M128533) was tested in parallel as a positive control, and in a similar way as test compound pre-treatment assay, i.e., 8 half log serial dilutions from start dose as 100 ug/mL. Plates were incubated at 37° C. and at 5% CO.sub.2.
[0126] On day 3 post-infection supernatant fluid from each compound concentration was collected and tested for virus titer using a standard endpoint dilution CCID.sub.50 assay and titer calculations using the Reed-Muench (1948) equation (Reed, L. J., 1938).
[0127] The in vitro SARS-COV-2 viral titer yield reductions by GH543 and positive control M128533 were summarized in Table 3. The concentration of compound required to reduce virus yield by 1 log 10 (EC.sub.90) was calculated by regression analysis, and concentration of the test compound that would cause 50% cell death in the absence of virus (CC.sub.50) was calculated in Table 4. The selective index of SI.sub.90 was calculated as CC.sub.50 divided by EC.sub.90.
TABLE-US-00003 TABLE 3 In vitro SARS COV-2 titer yield reduction results by VYR assay GH543.sup.a (nM) Virus Titer 200 6.7 63 5.3 20 3.3 6.3 1 2 <0.7 0.6 <0.7 0.2 5.7 0.06 6.7 .sup.aVirus titer for GH543 VYR as CCID.sub.50 per 0.1 mL, average virus control titers were 6.3 for the pre-treatment assay and 4.7 for the post-treatment assay. .sup.bVirus titer for M128533 VYR as CCID.sub.50 per 0.1 mL, average virus control titer was 6.0.
TABLE-US-00004 TABLE 4 In vitro anti SARS COV-2 activity by VYR assay Compound EC.sub.90 CC.sub.50 SI.sub.90 GH543 0.22 >200 >920 M128533 14 91 >6.4
[0128] The test compound GH543 was nontoxic (CC.sub.50, >200 nM) and active against SARS-CoV-2, and showed significant virus titer reductions (EC.sub.90, 0.22 nM), though the dose-response was not typical and higher concentrations did not inhibit CPE fully as lower concentrations did (Table 4, ignored for EC.sub.90 calculation). The selective index ratio was high (SI.sub.90>920) which is a good indication for a more effective and safer drug would be during in vivo treatment for a given viral infection. The positive control compound M128533 performed as expected.
[0129] GH543 reduces significantly virus infection and replication (EC.sub.90=0.22 nM) compare to positive control (EC.sub.90=14 nM), and the test compound is non-toxic to cells. Study provided evidence that could be a tool for inhibition of SARS-CoV-2.
REFERENCES CITED
[0130] Baranov, P. V., Henderson, C. M., Anderson, C. B., Gesteland, R. F., Atkins, J. F., Howard, M. T., (2005). Programmed ribosomal frameshifting in decoding the SARS-CoV genome. Virology, 332, 498-510. [0131] Beaucage, S. L., Caruthers, M. H. (1981). Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22, 1859-1862. [0132] Behlke, M. A. (2008). Chemical Modification of siRNAs for In Vivo Use. Oligonucleotides 18, 305-320. [0133] Chan, J. F. et al. (2015). Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev., 28, 465-522. [0134] Chang, C. I., Yoo, J. W., Hong, S. W., Lee, S. E., Kang, H. S., Sun, X., Rogoff, H. A., Ban, C., Kim, S., Li, C. J., Lee, D. K. (2009). Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol. Ther. 17, 725-732. [0135] Davidson, B. L., McCray, P. B. Jr. (2011). Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329-340. [0136] Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., Ribas, A. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070. [0137] Elbashir, S. M., Lendeckel, W., Tuschl, T. (2001). RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188-200. [0138] Fabian, M. R., Sonenberg, N., Filipowicz, W. (2010). Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351-379. [0139] Fisher, D., Heymann, D. (2020). Q&A: The novel coronavirus outbreak causing COVID-19. BMC Med, 18, 57. [0140] Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., Linsley, P. S., (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 21, 635-637. [0141] Jinek, M., Doudna, J. A. (2009). A three-dimensional view of the molecular machinery of RNA interference. Nature 457, 405-412. [0142] Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J., Yamasaki, S., Itaya, M., Pan, Y., Appukuttan, B. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597. [0143] Lu, M., Zhang, Q., Deng, M., Miao, J., Guo, Y., Gao, W., Cui, Q. (2008). An analysis of human microRNA and disease associations. PLoS One 3.10 e3420. [0144] Marra Jones, S. J., Astell, et al. (2003). The genome sequence of the SARS-associated coronavirus. Science, 300, 1399-1404. [0145] Masters, P. S., (2006). The molecular biology of coronaviruses. Adv. Virus Res., 66, 193-292. [0146] Peiris, J. S., Guan, Y., Yuen, K. Y., (2004). Severe acute respiratory syndrome. Nat. Med., 10, S88-S97. [0147] Rayner, S., Brignac, S., Bumeister, R., Belosludtsev, Y., Ward, T., Grant, O., O'Brien, K., Evans, G. A., Garner, H. R. (1998). Mermade: An Oligodeoxyribonucleotide Synthesizer for High Throughput Oligonucleotide Production in Dual 96-Well Plates. Genome Res. 8, 741-747. [0148] Reese, C. B. (2005). Oligo- and poly-nucleotides: 50 years of chemical synthesis. Org. Biomol. Chem. 3, 3851-3868. [0149] Scacheri, P. C., Rozenblatt-Rosen, O., Caplen, N.J., Wolfsberg, T. G., Umayam, L., Lee, J. C., Hughes, C. M., Shanmugam, K. S., Bhattacharjee, A., Meyerson, M., Collins, F. S. (2004). Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. U.S.A 101, 1892-1897. [0150] Shabalina, S. A., Koonin, E. V. (2008). Origins and evolution of eukaryotic RNA interference. Trends Ecol. Evol. 23, 578-587. [0151] Sun, X., Rogoff, H. A., Li, C. J., (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat. Biotechnol. 26, 1379-1382. [0152] van Boheemen, S. et al. (2012). Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3, e00473-12. [0153] Wilson R. C., Doudna, J. A. (2013). Molecular mechanisms of RNA interference. Annu Rev Biophys. 42, 217-239. [0154] Xu, X., Liu, Y., Weiss, S., Arnold, E., Sarafianos, S. G., Ding, J., (2003). Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res., 31, 7117-7130. [0155] Zhou P, Yang X, Wang X, et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579, 270-273. [0156] Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 382, 727-733. [0157] Sun, X., Rogoff, H. & Li, C. (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat. Biotechnol., 26, 1379-1382. [0158] Kunisaki, K. M., and Janoff, E. N. (2009). Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9, 493-504. [0159] Hodgson, J. (2020). The pandemic pipeline. Nat. Biotechnol. 38, 523-532. [0160] Lu, H. (2020). Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. [0161] Levanova, A., and Poranen, M. M. (2018). RNA interference as a prospective tool for the control of human viral infections. Front. Microbiol. 9, 2151. [0162] Lam, J. K., Chow, M. Y., Zhang, Y., and Leung, S. W. (2015). siRNA versus miRNA as therapeutics for gene silencing. Mol. Ther. Nucleic Acids 4, e252. [0163] Borenfreund E., Puerner J. A. (1984) A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTDNR90). Journal of Tissue Culture Methods 9(1):7-9. [0164] Borenfreund E., Puerner J. A. (1984) A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTDNR90). Journal of Tissue Culture Methods 9(1):7-9.